Study M741
Study name | MahmoudianDehkordi S 2021 |
Title | Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression |
Overall design | In this study, the authors used a targeted metabolomics approach utilizing a panel of 180 metabolites to gain insights into mechanisms of action and response to citalopram/escitalopram. Plasma samples from 136 participants with major depressive disorder (MDD) were profiled at baseline and after 8 weeks of citalopram/escitalopram treatment. Baseline metabolites that differentiate between patients who have benefitted substantially (HRSD17 <= 7; remitter group) after 8 weeks of treatment vs. those who gained no meaningful benefits with SSRI treatment (<30% reduction in HRSD17 from baseline to week 8; non-remitter group) were also identified. |
Study Type | Type2; Type4; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-IV diagnosed MDD, HAMD-17 > 14 |
Sample size | 136 |
Tissue | Peripheral; Blood; Plasma; |
Platform | MS-based; LC-MS: ACQUITY UPLC System (Waters Corporation) with Xevo TQ-S triple quadrupole mass spectrometer (Waters Corporation); |
PMID | |
DOI | |
Citation | MahmoudianDehkordi S, Ahmed AT, Bhattacharyya S, et al. Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression. Transl Psychiatry. 2021 Mar 2;11(1):153. |
Metabolite | L-Proline; L-Tyrosine; L-Arginine; Propionylcarnitine; Butyrylcarnitine; Serotonin; L-Acetylcarnitine; Aminoadipic acid; Sarcosine; Stearoylcarnitine; L-Octanoylcarnitine; Decanoylcarnitine; Dodecanoylcarnitine; Methionine sulfoxide; L-Palmitoylcarnitine; Octadecenoylcarnitine; Hydroxyvalerylcarnitine; Valerylcarnitine; PC aa C36:1; PC aa C30:0; PC aa C42:2; PC aa C34:4; PC aa C34:3; PC aa C40:2; PC aa C24:0; PC aa C28:1; PC aa C36:6; PC aa C42:4; PC ae C34:3; PC ae C38:2; PC ae C36:3; PC ae C34:2; PC ae C30:0; PC ae C42:2; SM C24:0; LysoPC a C28:1; LysoPC a C24:0; LysoPC a C28:0; Hexadecenoylcarnitine; Octadecadienylcarnitine; Tetradecadienylcarnitine; Hydroxytetradecenoylcarnitine; Pimelylcarnitine; Hydroxyhexadecenoylcarnitine; Hydroxyhexadecadienylcarnitine; Hydroxyoctadecenoylcarnitine; Tetradecenoylcarnitine; |
